• Corpus ID: 39500835

How to convert from traditional cyclosporine to the microemulsion formulation in stable renal transplant patients?

  title={How to convert from traditional cyclosporine to the microemulsion formulation in stable renal transplant patients?},
  author={Flavio Gaspari and Norberto Perico and Roberto Pisoni and M F Anedda and O Signorini and Raffaele Caruso and Eliana Gotti and Giuseppe Remuzzi},
  journal={Clinical transplantation},
  volume={12 5},
How to convert from traditional cyclosporine (CsA) to the microemulsion formulation in stable renal transplant patients is still a matter of debate. The present study was designed to evaluate the effects of changeover from traditional Sandimmune to Neoral formulation at two dose-ratio conversions on CsA pharmacokinetics, safety and tolerability particularly in terms of renal function. Thirty outpatients regularly followed at our Clinical Research Center were randomized to 1:1 or 1:0.75 dose… 
Three Generations of Cyclosporine A Formulations: An In Vitro Comparison
It became clear that when compared under simple physical conditions, established cyclosporine formulations and new generic products show significant differences in droplet size and distribution between an aqueous phase and a high fat content food.
Generic cyclosporine formulations: more open questions than answers
Converting patients from Neoral to the new generic CsA formulations could be detrimental, exposing patients to increased risk of graft function deterioration and graft loss.
Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation.
The introduction of cyclosporin microemulsion has consolidated the place of the drug as a mainstay of therapy in all types of solid organ transplantation and savings in direct healthcare costs in kidney or liver transplantation are shown, although studies incorporating indirect costs or expressing costs in terms of therapeutic outcomes are currently unavailable.
Cyclosporine Formulation and Kaposi’s Sarcoma after Renal Transplantation
In recipients of kidney transplant CsA Neoral increases the risk of KS as compared to the Sandimmune formulation, possibly due to enhanced drug bioavailability and ultimately patients daily Cs a exposure.
Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow-up randomized, controlled clinical trial.
In renal transplant recipients who were on immunosuppressive therapy with the cyclosporine microemulsion Neoral, mycophenolate mofetil (MMF) was not better than azathioprine in preventing acute rejection at 21 mo after transplantation and was 15 times more expensive.
Limited Sampling Strategies for Estimating Cyclosporin Area Under the Concentration–Time Curve: Review of Current Algorithms
This article reviews the current literature on estimating cyclosporin AUC using limited sampling strategy (LSS) and suggests that equations defined on one transplant type may be applicable to other transplant types, to both adults and children, and to early or late after transplantation.
Revisiting Traditional Risk Factors for Rejection and Graft Loss After Kidney Transplantation
  • T. Dunn, H. Noreen, A. Matas
  • Medicine
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2011
The presence of DSA is an important predictor of rejection risk, in contrast to traditional risk factors, and further development of immunosuppressive protocols will be facilitated by stratification of rejectionrisk by donor sensitization.